Literature DB >> 25915977

Identification and description of the axillary web syndrome (AWS) by clinical signs, MRI and US imaging.

O Leduc, E Fumière, S Banse, C Vandervorst, A Clément, T Parijs, F Wilputte, F Maquerlot, M Ezquer Echandia, A Tinlot, A Leduc.   

Abstract

The Axillary Web Syndrome (AWS) follows surgery for breast neoplasia and consists of one, or more frequently two or three, cords of subcutaneous tissue. Cords originate from the axilla, spread to the antero-medial surface of the arm down to the elbow and then move into the antero-medial aspect of the forearm and sometimes into the root of the thumb. The purpose of this study was to compare two techniques, ultrasound (US) and Magnetic Resonance Imaging (MRI) for their sensitivity and accuracy in identifying AWS cords and to provide insights to the origin of this pathology. US examinations were performed on fifteen patients using a high frequency probe (17 MHz). We first palpated and marked the cord with location aided by maximum abduction. To identify the cord with MRI (1.5 Tesla), a catheter filled with a gel detectable under MRI was placed on the skin at the site of the cord. We found that in some US cases, the dynamic abduction maneuver was essential to facilitate detection of the cord. This dynamic method on ultrasound confirmed the precise location of the cord even if it was located deeper in the hypodermis fascia junction. US and MRI images revealed features of the cords and surrounding tissues. Imaging the cords was difficult with either of the imaging modalities. However, US seemed to be more efficient than MRI and allowed dynamic evaluation. Overall analysis of our study results supports a lymphatic origin of the AWS cord.

Entities:  

Mesh:

Year:  2014        PMID: 25915977

Source DB:  PubMed          Journal:  Lymphology        ISSN: 0024-7766            Impact factor:   1.286


  7 in total

Review 1.  Axillary Web Syndrome in Breast Cancer: A Prevalent But Under-Recognized Postoperative Complication.

Authors:  Susan R Harris
Journal:  Breast Care (Basel)       Date:  2018-02-01       Impact factor: 2.860

2.  Patients who report cording after breast cancer surgery are at higher risk of lymphedema: Results from a large prospective screening cohort.

Authors:  Cheryl L Brunelle; Sacha A Roberts; Amy M Shui; Tessa C Gillespie; Kayla M Daniell; George E Naoum; Alphonse Taghian
Journal:  J Surg Oncol       Date:  2020-06-04       Impact factor: 3.454

3.  Function, Shoulder Motion, Pain, and Lymphedema in Breast Cancer With and Without Axillary Web Syndrome: An 18-Month Follow-Up.

Authors:  Linda A Koehler; David W Hunter; Anne H Blaes; Tufia C Haddad
Journal:  Phys Ther       Date:  2018-06-01

4.  Axillary web syndrome assessment using a self-assessment questionnaire: a prospective cohort study.

Authors:  F Baggi; Luiz Felipe Nevola Teixeira; S Gandini; M C Simoncini; E Bonacossa; F Sandrin; M Sciotto Marotta; G Lanni; P Dadda; D Colpani; A Luini
Journal:  Support Care Cancer       Date:  2018-03-05       Impact factor: 3.603

5.  Randomised clinical trial of a manual therapy programme to reduce the evolution time of axillary web syndrome in women affected by breast cancer: study protocol.

Authors:  Jesús Baltasar González Rubino; Maria Jesus Vinolo-Gil; Cristina García Muñoz; Rocío Martín-Valero
Journal:  BMJ Open       Date:  2022-09-21       Impact factor: 3.006

6.  Lymphoscintigraphic Investigations for Axillary Web Syndromes.

Authors:  Mirela Mariana Roman; Romain Barbieux; Christine Eddy; Clarence Karler; Isabelle Veys; Assaf Zeltzer; Nele Adriaenssens; Olivier Leduc; Pierre Bourgeois
Journal:  Lymphat Res Biol       Date:  2021-11-22       Impact factor: 2.349

7.  Effects of a physical therapy program combined with manual lymphatic drainage on shoulder function, quality of life, lymphedema incidence, and pain in breast cancer patients with axillary web syndrome following axillary dissection.

Authors:  Youngki Cho; Junghwa Do; Sunyoung Jung; Ohyun Kwon; Jae Yong Jeon
Journal:  Support Care Cancer       Date:  2015-11-05       Impact factor: 3.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.